Follow us on Twitter
twitter icon@FreshPatents


Allergy patents

      

This page is updated frequently with new Allergy-related patent applications.

SALE: 60+ Allergy-related patent PDFs



 Effector-deficient anti-cd32a antibodies patent thumbnailnew patent Effector-deficient anti-cd32a antibodies
Effector-deficient anti-cd32a monoclonal antibodies are encompassed, as are method and uses for treating cd32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.. .
Adventist Health System/sunbelt Inc.


 Air purification method and apparatus patent thumbnailnew patent Air purification method and apparatus
An air purification method for use in an apparatus is provided. The air purification method includes: acquiring plant information associated with one or more plants located in a target detection region; determining, based on the plant information and predetermined reference plant information of an allergy-causing plant, that the target detection region contains the allergy-causing plant and the allergy-causing plant is in a blooming state; and in response to the determining, enabling an air purification function of an air purification device..
Xiaomi Inc.


 Sirp polypeptide compositions and methods of use patent thumbnailSirp polypeptide compositions and methods of use
Provided herein are sirp-gamma, sirp-beta or sirp-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.. .
Ab Initio Biotherapeutics, Inc.


 Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor patent thumbnailBenzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv


 Method and means for diagnosing and treating allergy patent thumbnailMethod and means for diagnosing and treating allergy
Disclosed is a method for diagnosing allergy in a human or animal patient, wherein the level of species-specific lipocalin, especially lipocalin 2 in a human patient, is measured in a sample of said patient and wherein a lowered level of said lipocalin compared to the level of said lipocalin in the corresponding sample of a human or animal that has no allergy, is indicative of an allergy, as well as a kit for performing this method, and a kit for quality control of allergen molecules or extracts used for immunotherapy of allergy by determining its siderophore-iron ligand load and thus immunomodulatory potency. Further, lipocalin proteins for use in treatment or prevention of allergies are provided, preferably complexed with siderophore-iron ligands..
Biomedical International R+d Gmbh


 Methods and devices for allergy testing and treatment patent thumbnailMethods and devices for allergy testing and treatment
A method of testing a patient for allergies includes obtaining from the patient a blood sample having an original volume of at most 0.5 ml, and testing the blood sample for ige reactive with antigens from a plurality of allergen sources by multiple elisa. The blood sample may be taken from the patient in a clinic, and/or the blood sample may be taken by a physician without venipuncture.
Spiriplex, Inc


 Method of preventing allergies patent thumbnailMethod of preventing allergies
The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children.
Dbv Technologies


 Supplement for improving immunotolerance, intestinal environment and intestinal tract barrier patent thumbnailSupplement for improving immunotolerance, intestinal environment and intestinal tract barrier
A supplement for improving immunotolerance, intestinal environment and intestinal tract barrier for the purpose of improving intestinal vulnerability, food intolerance or allergy, systemic allergy, autoimmune diseases and systemic inflammatory diseases by immune reactions which is obtained by mixing an ingredient (a) comprising at least one of a probiotic that is any one of lactic acid bacteria, lactobacillus bifidus, saccharified bacteria, natto bacteria and yeast fungus, or a mixture thereof, a biogenic that is a bacteria-producing substance such as lactic acid bacteria, and a prebiotic is indigestible food ingredients such as oligosaccharide, dietary fiber, substance stimulating production of lactobacillus bifidus, and others or a mixture thereof and an ingredient (b) comprising at least one of l-glutamine, zinc, vitamin a and vitamin d.. .

 Treatment of celiac disease, c. difficile infection, food intolerance and food allergy with secretory iga/igm patent thumbnailTreatment of celiac disease, c. difficile infection, food intolerance and food allergy with secretory iga/igm
A process is provided for inhibiting symptoms of celiac disease, clostridium difficile associated diseases such as clostridium difficile colitis, pseudomembranous colitis and antibiotic associated diarrhea, food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an igm. When administered in a, therapeutic quantity based on the subject characteristics and the type of igm, symptoms of food allergy or food intolerance in that subject are inhibited.

 Programming of cells for tolerogenic therapies patent thumbnailProgramming of cells for tolerogenic therapies
Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease..
Forsyth Dental Infirmary For Children


Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Methods for treating allergic airway inflammation

Provided herein are methods for treating a symptom and/or clinical sign associated with an allergy that includes neutrophil recruitment, such as allergic airway inflammation. In one embodiment, the method includes administering to a subject a composition that includes a cxcr2 inhibitor, a md2 inhibitor, a myd88 inhibitor, or a combination thereof.

Glucopyranosyl lipid a and allergen formulations for sublingual administration

The present application relates to compositions and methods for treating allergy, e.g., peanut allergy, in patients. The methods involve administering glucopyranosyl lipid adjuvant (gla) and peanut allergen(s) to the patient via a sublingual route..
Sanofi

Uses of kappa opioid synthetic peptide amides

The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.

Sirna and their use in methods and compositions for inhibiting the expression of the orai1 gene

The invention relates to si rna molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the orai1 gene. The invention also relates to the use of said si rnas molecules in the treatment and/or prevention of an eye condition characterised by increased expression and/or activity of orai1 gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis..
Sylentis Sau

Sirna and their use in methods and compositions for inhibiting the expression of the flap gene

The invention relates to si rna molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the flap gene. The invention also relates to the use of said si rnas molecules in the treatment and/or prevention of an eye condition characterised by increased expression and/or activity of flap gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis..
Sylentis Sau

Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations

Heat treated bifidobacterium lactis ncc 2818 reduces the symptoms of allergies in different groups of patients, such as allergies originating from food allergens in young children, or infants, and food, respiratory and cutaneous allergens in children, adults and household pets. The heat treated bifidobacterium lactis ncc 2818 may be administered alone or in a composition.
Nestec S.a.

Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

The present invention relates to the compound according to formula i, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons. In particular, the compound inhibits jak a family of tyrosine kinases, and more particularly jak1.

Tolerogenic synthetic nanocarriers for allergy therapy

Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and mhc class ii-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.. .
Selecta Biosciences, Inc.

Methods of treating allergies and autoimmune diseases with homogenate of axenic c. elegans

Methods of using axenic c. Elegans homogenate for treating allergies or an autoimmune disease are disclosed.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Rna interference is provided for inhibition of spleen tyrosine kinase (syk) mrna expression, in particular, for treating patients having a syk-related inflammatory condition or at risk of developing a syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.. .
Arrowhead Pharmaceuticals, Inc.

Benzazepine dicarboxamide compounds

Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Compositions and methods for combination ingredient delivery

Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either..
The Fix, Llc

Peptide combinations and uses thereof in treating dust mite allergy

The invention relates to combinations of peptides or variants thereof derived from a portion of an amino sequence of cm a house dust mite allergen, e.g. The allergens der p 1, der f 1, der p 2 and/or der f 2.
La Jolla Institute For Allergy And Immunology

Glycotargeting therapeutics

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.. .
Ecole Polytechnique Federale De Lausanne (epfl)

Sirna and their use in methods and compositions for inhibiting the expression of the pdk1 gene

The invention relates to sirna molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the pdk1 gene. The invention also relates to the use of said sirnas molecules in the treatment and/or prevention of an eye condition characterised by increased expression and/or activity of pdk1 gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis..
Sylentis Sau

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Amorphous magnesium-substituted calcium phosphate compositions and their uses

Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.. .
Medical Research Council

Method of inducing tolerance to an allergen

The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy.
Murdoch Childrens Research Institute

Toothpaste for delivery of allergens to oral mucosa

Pro-toothpaste compositions formulated to receive a volume of allergen solution to provide toothpastes that exhibit efficacy for oral mucosal immunotherapy (omit) and acceptable consumer and product stability properties, along with kits of pro-toothpaste, allergen/extracts of allergens, and optionally compounding means and/or specialized toothbrushes are provided. Toothpastes suitable and effective for omit and methods for managing allergic symptoms and for reducing risk of allergy in people without symptoms employing the pro-toothpastes, toothpastes and kits of the invention are also disclosed..
Allovate, Llc

Allergy testing tray

An allergy testing kit contains a plurality of allergy testing applicators, an allergy testing tray and a plurality of allergen bottles each containing an allergen. Each of the applicators contains an elongated handle, a plurality of arms extending from the elongated handle and disposed in an asymmetrical configuration, and a plurality of legs with tines extending from each of the arms.

Method of testing for allergies

An allergy testing kit contains a plurality of allergy testing applicators, an allergy testing tray and a plurality of allergen bottles each containing an allergen. Each of the applicators contains an elongated handle, a plurality of arms extending from the elongated handle and disposed in an asymmetrical configuration, and a plurality of legs with tines extending from each of the arms.

Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)

The present invention provides in vitro and in vivo diagnostic tests and methods for determining the safety, efficacy, or outcome of allergen-specific immunotherapy (sit) in a patient. The present invention also provides for the measurement of allergen specific igg and ige in a patient tissue sample, or extract thereof, or in a biological fluid or blood sample, and determining whether the allergen-specific immunoglobulins contained in the patient sample(s), upon injection into an allergen-sensitized animal, will protect the animal following challenge with the allergen.
Regeneron Pharmaceuticals, Inc.

Composition comprising peptide derived from adiponectin

Provided is a pharmaceutical or cosmetic composition comprising adiponectin-derived peptide fragments, i.e., the peptides of seq id nos: 1 to 6 as an active ingredient. The peptides facilitate skin regeneration and moisturization, inhibit skin wrinkle, and have inhibitory activities against allergy and inflammation as well as metastasis of cancer cells..
Supadelixir Inc.

Allergy testing kit

An allergy testing kit contains a plurality of allergy testing applicators, an allergy testing tray and a plurality of allergen bottles each containing an allergen. Each of the applicators contains an elongated handle, a plurality of arms extending from the elongated handle and disposed in an asymmetrical configuration, and a plurality of legs with tines extending from each of the arms.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Human immune therapies using a cd27 agonist alone or in combination with other immune modulators

Methods of inducing t cell proliferation and expansion in vivo for treating conditions wherein antigen-specific t cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one cd27 agonist, preferably an agonistic cd27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-cd40, ox-40, 4-1bb, or ctla-4 antibody or an agent that depletes regulatory cells, or a cytokine.
University Of Southampton

Novel compound useful for the treatement of degenerative and inflammatory diseases

A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity

The present invention relates to the preparation and use of variants of the group 5 allergen of the pooideae which are characterised by reduced ige reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with t lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies..
Merck Patent Gmbh

Allergy skin test devices with surrounding pain-reduction structures

An allergy skin testing device is disclosed that includes at least one central post having at least one sharp probe extending longitudinally from an end of the at least one central post, the at least one sharp probe being for administering an allergen to skin. For each central post, at least three dull probes substantially surround the at least one sharp probe, creating a “pain gate fence”, the at least three dull probes being for activating a pain gate effect affecting nerves of the skin while the at leat one sharp probe administers the allergen to the skin.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

A purified extract isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma

A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a ova-sensitized/challenged mouse model..
Korea Research Institute Of Bioscience And Biotechnology



Allergy topics:
  • Autoimmune
  • Prophylactic
  • Ophthalmic
  • Autoimmune Disorder
  • Immune Disorder
  • Dermatitis
  • Staurosporin
  • Aspergillosis
  • Angioedema
  • Allergic Rhinitis
  • Food Allergy
  • Therapeutical
  • Bronchopulmonary
  • Staurosporine
  • Sudden Infant Death


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Allergy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergy with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.7609

    file did exist - 2263

    0 - 1 - 51